No Data
No Data
Express News | Foghorn Therapeutics Inc. Files for Common Stock Offering of up to $190 Mln - SEC Filing
Foghorn Therapeutics Unveils August 2024 Investor Presentation
Foghorn Therapeutics | 10-Q: Quarterly report
Foghorn Therapeutics 2Q Research and Development Expenses $23.8M >FHTX
Express News | Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
Express News | Foghorn Therapeutics Q2 Collaboration Revenue USD 6.888 Million
No Data